CA-MANSCAPED-INC
You ready to rock the landscaped look? Let’s get mowin’. Today, MANSCAPED™ , the global leader and category creator of men’s below-the-waist grooming, announces the international launch of its fourth-generation electric trimmer, The Lawn Mower® 4.0 . Designed and engineered specifically for groin and body grooming, the brand’s newest masterpiece focuses on intelligent functionality, maximum performance and, of course, a superior below-the-waist grooming experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210721005277/en/
What’s more, The Lawn Mower 4.0 has been integrated into MANSCAPED’s thoughtfully curated bundles for the ultimate self-care routine. The hotly anticipated device and newly elevated kits are now shipping to the United Kingdom , the European Union , Norway , Switzerland , Australia , and New Zealand , in addition to the United States and Canada.
“The global launch of The Lawn Mower 4.0 and our newest packages means getting our latest and most exciting innovations into the hands of millions of men all over the world,” said Paul Tran, Founder and CEO of MANSCAPED. “It’s milestones like these that further advance our vision of driving the movement that changes the face of male grooming — something we’re both humbled by and proud to do every day and with every launch.”
What can you expect with the latest and greatest debuting from the global grooming giant? We’re glad you asked...
The Lawn Mower® 4.0 Groin Trimmer
Proven product attributes and state-of-the-art upgrades come together to make this tool the marquee groin and body trimmer on the market.
Core Features:
- SkinSafe® technology to help reduce the risk of nicks, snags, and tugs
- Powerful 7,000 RPM motor with QuietStroke™ technology
- Rechargeable 600 mAh li-ion battery
- Waterproof design for convenient wet or dry operation
New Enhancements:
- Wireless charging system with electromagnetic induction
- 4000k LED spotlight with diffuser so you can see where you’re trimming
- Cutting-edge ceramic blade to help reduce grooming accidents
- Adjustable trimming guard sizes 1 to 4, with 3, 6, 10, or 13mm settings
- Modern two-toned black finish and powerful packaging presentation
- Travel lock for safety - and racking up frequent flier miles
To up-level your grooming game, or give the greatest gift ever, consider exploring MANSCAPED’s luxury kits that combine The Lawn Mower 4.0 with an array of other top-selling tools, formulations, and accessories. When used together, cleanliness and confidence are abounding.
- The Lawn Mower 4.0 Groin Trimmer
- Crop Preserver® Ball Deodorant - Avoid stenchy under regions and the dreaded “swamp crotch”; infused with cooling aloe vera, this formulation helps combat sweat and unwanted odor down there
- Crop Reviver® Ball Toner - This spray is the solution for maintaining hygiene and freshness, especially when on-the-go; relieve high-friction areas and post-shave irritation with just a spritz
- This bundle’s free gifts include The Shed premium travel bag and the much acclaimed MANSCAPED™ Boxers made with a microfiber blend
Add another essential men's grooming tool into the mix with this kit featuring MANSCAPED’s premier above-the-waist tool.
- The Weed Whacker® Nose & Ear Hair Trimmer - MANSCAPED redesigned the traditional nose hair taming device by focusing on the highest performance and comfort; equipped with SkinSafe technology, a 9,000 RPM motor, and 360-degree rotary dual-blade system
- The Lawn Mower 4.0 Groin Trimmer
- Crop Preserver Ball Deodorant
- Crop Reviver Ball Toner
- The Shed & MANSCAPED Boxers
To learn more and to purchase any of these new products or packages, visit MANSCAPED.com, a one-stop-shop destination website designed for customers in the United Kingdom, European Union, Norway, Switzerland, Australia, New Zealand, Canada and more regions to come this year.
About MANSCAPED™:
Founded by Paul Tran in 2016, San Diego, California-based MANSCAPED is the global leader in men's grooming and hygiene below-the-waist, trusted by over 2 million men worldwide. The product range includes only the best tools, formulations, and accessories for a simple, effective, and elevated male grooming routine. MANSCAPED offers a one-stop-shop at manscaped.com and direct-to-consumer shipping in more than 30 countries, spanning the United States, Canada, Australia, New Zealand, the United Kingdom, the European Union, Norway, and Switzerland. Select products and unique bundles can also be found on Amazon with Prime and pickup options available. Retail placement includes Target, Best Buy, and Macy’s stores throughout the U.S. and Hairhouse locations in Australia. For more information, visit the website or follow on Facebook , Instagram , Twitter , TikTok , YouTube , and Triller.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005277/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom